These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

200 related articles for article (PubMed ID: 37760422)

  • 1. Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI.
    de Godoy LL; Lim KC; Rajan A; Verma G; Hanaoka M; O'Rourke DM; Lee JYK; Desai A; Chawla S; Mohan S
    Cancers (Basel); 2023 Sep; 15(18):. PubMed ID: 37760422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Noninvasive assessment of isocitrate dehydrogenase mutation status in cerebral gliomas by magnetic resonance spectroscopy in a clinical setting.
    Tietze A; Choi C; Mickey B; Maher EA; Parm Ulhøi B; Sangill R; Lassen-Ramshad Y; Lukacova S; Østergaard L; von Oettingen G
    J Neurosurg; 2018 Feb; 128(2):391-398. PubMed ID: 28298040
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Preoperative Determination of Isocitrate Dehydrogenase Mutation in Gliomas Using Spectral Editing MRS: A Prospective Study.
    Nguyen TB; Melkus G; Taccone M; Moldovan ID; Ghinda D; Gotfrit R; Torres CH; Zakhari N; Chakraborty S; Woulfe J; Jansen G; McInnes MD; Thornhill RE; Cameron I; AlKherayf F
    J Magn Reson Imaging; 2021 Feb; 53(2):416-426. PubMed ID: 32940938
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intraoperative assessment of isocitrate dehydrogenase mutation status in human gliomas using desorption electrospray ionization-mass spectrometry.
    Alfaro CM; Pirro V; Keating MF; Hattab EM; Cooks RG; Cohen-Gadol AA
    J Neurosurg; 2019 Jan; 132(1):180-187. PubMed ID: 30611146
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative Value of 2-Hydroxyglutarate-to-Lipid and Lactate Ratio versus 2-Hydroxyglutarate Concentration on MR Spectroscopic Images for Predicting Isocitrate Dehydrogenase Mutation Status in Gliomas.
    Suh CH; Kim HS; Park JE; Jung SC; Choi CG; Woo DC; Lee HB; Kim SJ
    Radiol Imaging Cancer; 2020 Jul; 2(4):e190083. PubMed ID: 33778723
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The diagnostic efficiency of integration of 2HG MRS and IVIM versus individual parameters for predicting IDH mutation status in gliomas in clinical scenarios: A retrospective study.
    Yu M; Ge Y; Wang Z; Zhang Y; Hou X; Chen H; Chen X; Ji N; Li X; Shen H
    J Neurooncol; 2024 Apr; 167(2):305-313. PubMed ID: 38424338
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnostic accuracy of 2-hydroxyglutarate magnetic resonance spectroscopy in newly diagnosed brain mass and suspected recurrent gliomas.
    Zhou M; Zhou Y; Liao H; Rowland BC; Kong X; Arvold ND; Reardon DA; Wen PY; Lin AP; Huang RY
    Neuro Oncol; 2018 Aug; 20(9):1262-1271. PubMed ID: 29438510
    [TBL] [Abstract][Full Text] [Related]  

  • 8. 2-Hydroxyglutarate magnetic resonance spectroscopy in adult brainstem glioma.
    Iwahashi H; Nagashima H; Tanaka K; Uno T; Hashiguchi M; Maeyama M; Somiya Y; Komatsu M; Hirose T; Itoh T; Sasaki R; Sasayama T
    J Neurosurg; 2023 Aug; 139(2):355-362. PubMed ID: 36708540
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Accumulation of 2-hydroxyglutarate in gliomas correlates with survival: a study by 3.0-tesla magnetic resonance spectroscopy.
    Natsumeda M; Igarashi H; Nomura T; Ogura R; Tsukamoto Y; Kobayashi T; Aoki H; Okamoto K; Kakita A; Takahashi H; Nakada T; Fujii Y
    Acta Neuropathol Commun; 2014 Nov; 2():158. PubMed ID: 25376594
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In vivo 2-hydroxyglutarate-proton magnetic resonance spectroscopy (3 T, PRESS technique) in treatment-naïve suspect lower-grade gliomas: feasibility and accuracy in a clinical setting.
    Cuccarini V; Antelmi L; Pollo B; Paterra R; Calatozzolo C; Nigri A; DiMeco F; Eoli M; Finocchiaro G; Brenna G; Tramacere I; Bruzzone MG; Anghileri E
    Neurol Sci; 2020 Feb; 41(2):347-355. PubMed ID: 31650436
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Spectroscopic imaging of D-2-hydroxyglutarate and other metabolites in pre-surgical patients with IDH-mutant lower-grade gliomas.
    Autry AW; Lafontaine M; Jalbert L; Phillips E; Phillips JJ; Villanueva-Meyer J; Berger MS; Chang SM; Li Y
    J Neurooncol; 2022 Aug; 159(1):43-52. PubMed ID: 35672531
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Non-invasive detection of 2-hydroxyglutarate in IDH-mutated gliomas using two-dimensional localized correlation spectroscopy (2D L-COSY) at 7 Tesla.
    Verma G; Mohan S; Nasrallah MP; Brem S; Lee JY; Chawla S; Wang S; Nagarajan R; Thomas MA; Poptani H
    J Transl Med; 2016 Sep; 14(1):274. PubMed ID: 27659543
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prospective Longitudinal Analysis of 2-Hydroxyglutarate Magnetic Resonance Spectroscopy Identifies Broad Clinical Utility for the Management of Patients With IDH-Mutant Glioma.
    Choi C; Raisanen JM; Ganji SK; Zhang S; McNeil SS; An Z; Madan A; Hatanpaa KJ; Vemireddy V; Sheppard CA; Oliver D; Hulsey KM; Tiwari V; Mashimo T; Battiste J; Barnett S; Madden CJ; Patel TR; Pan E; Malloy CR; Mickey BE; Bachoo RM; Maher EA
    J Clin Oncol; 2016 Nov; 34(33):4030-4039. PubMed ID: 28248126
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Integration of 2-hydroxyglutarate-proton magnetic resonance spectroscopy into clinical practice for disease monitoring in isocitrate dehydrogenase-mutant glioma.
    de la Fuente MI; Young RJ; Rubel J; Rosenblum M; Tisnado J; Briggs S; Arevalo-Perez J; Cross JR; Campos C; Straley K; Zhu D; Dong C; Thomas A; Omuro AA; Nolan CP; Pentsova E; Kaley TJ; Oh JH; Noeske R; Maher E; Choi C; Gutin PH; Holodny AI; Yen K; DeAngelis LM; Mellinghoff IK; Thakur SB
    Neuro Oncol; 2016 Feb; 18(2):283-90. PubMed ID: 26691210
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Incorporation of edited MRS into clinical practice may improve care of patients with IDH-mutant glioma.
    Nichelli L; Cadin C; Lazzari P; Mathon B; Touat M; Sanson M; Bielle F; Marjańska M; Lehéricy S; Branzoli F
    AJNR Am J Neuroradiol; 2024 Jul; ():. PubMed ID: 38997123
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of IDH and TERTp mutation status using
    Ozturk-Isik E; Cengiz S; Ozcan A; Yakicier C; Ersen Danyeli A; Pamir MN; Özduman K; Dincer A
    J Magn Reson Imaging; 2020 Jun; 51(6):1799-1809. PubMed ID: 31664773
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vivo MRS measurement of 2-hydroxyglutarate in patient-derived IDH-mutant xenograft mouse models versus glioma patients.
    Tiwari V; Mashimo T; An Z; Vemireddy V; Piccirillo S; Askari P; Hulsey KM; Zhang S; de Graaf RA; Patel TR; Pan E; Mickey BE; Maher EA; Bachoo RM; Choi C
    Magn Reson Med; 2020 Sep; 84(3):1152-1160. PubMed ID: 32003035
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Echo-planar spectroscopic imaging with dual-readout alternated gradients (DRAG-EPSI) at 7 T: Application for 2-hydroxyglutarate imaging in glioma patients.
    An Z; Tiwari V; Ganji SK; Baxter J; Levy M; Pinho MC; Pan E; Maher EA; Patel TR; Mickey BE; Choi C
    Magn Reson Med; 2018 Apr; 79(4):1851-1861. PubMed ID: 28833542
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Highly specific determination of IDH status using edited in vivo magnetic resonance spectroscopy.
    Branzoli F; Di Stefano AL; Capelle L; Ottolenghi C; Valabrègue R; Deelchand DK; Bielle F; Villa C; Baussart B; Lehéricy S; Sanson M; Marjanska M
    Neuro Oncol; 2018 Jun; 20(7):907-916. PubMed ID: 29126125
    [TBL] [Abstract][Full Text] [Related]  

  • 20. 2-Hydroxyglutarate MR spectroscopy for prediction of isocitrate dehydrogenase mutant glioma: a systemic review and meta-analysis using individual patient data.
    Suh CH; Kim HS; Jung SC; Choi CG; Kim SJ
    Neuro Oncol; 2018 Nov; 20(12):1573-1583. PubMed ID: 30020513
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.